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Endodermal Sinus Tbmor in a 14-Year-Old Girl
Lorenzo C. Boyce, MD,* Kiran Balchandani, MD,* and Roshinder Padda, MD*

A case report on a 14-year-old girl with a large pelvic and abdominal mass is presented. Initial
evaluation suggested the mass to be of ovarian origin, and the diagnosis of endodermal sinus tumor
was confirmed by the pathological specimen. Alphafetoprotein (AFP) levels on admission were 12,700
mg/dL. but AFP decreased immediately in the postoperative period and has continued to decline
toward normal levels over the past four months of combination chemotherapy. After completion of
chemotherapy. AFP levels will continue to be monitored and a second-look procedure may be in order
(Henry Ford Hosp MedJ 1986;34:132-3)

E

ndodermal sinus tumor (EST) is the second most frequent
germ cell tumor ofthe ovaries. Once considered very rare,
the tumor is now diagnosed with greater frequency. Although
review of Henry Ford Hospital medical records revealed only
two other cases of EST, this number may be artifactually low
due to the changing classification and nomenclature of this
tumor
EST, because of its specific age incidence, may be considered
one of the most common, highly malignant ovarian neoplasms
of childhood, adolescence, and young adult life (1). EST is a
very aggressive tumor and until recently has carried a grave
prognosis, with most patients dying within 12 months of initial
diagnosis. However, since the introduction of combined chemotherapy in the mid-1960s, the prognosis of this disease has
improved. Preliminary reports on the use of combined chemotherapy in EST patients are encouraging, and in some cases
the success of combined chemotherapy will bring into question
the value of radical surgery and subsequent loss of childbearing
ability in those patients where the tumor is confined to one
ovary. The two-year survival rate following combination chemotherapy is over 90% for stage I and I I and less than 50% for
stage I I I and IV of the disease. A case report of a 14-year-old
patient with EST, stage I-A, is discussed herein.

Case Report
A 14-year-old obese female complaining of abdominal pain was
found to have a large abdominal mass upon examination by her pediatrician, who referred her to the Department of Gynecology at Henry Ford
Hospital. The patient had a history of asymptomatic bronchial asthma.
She was gravida 0 and para 0, and her last menstrual period was August
3, 1985. Three months prior to admission, the patient noted a sharp,
intermittent abdominal pain that worsened with movement. The pain
was located primarily in the left upper quadrant. One month later, she
noted an increase in abdominal girth despite her attempts at weight reduction. The patient also complained of nausea, vomiting, and an overall decrease in appetite. At the time of admission she complained of a
persistent left upper quadrant pain, which she described as sharp and
constant, possibly associated with emesis, and which was not relieved
by use of 500 mg acetaminophen. The patient stated that the pain had
become progressively worse during the week prior to admission. She
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denied any syncopal episodes, chest pain, shortness of breath, diarrhea, constipation, or recent abdominal trauma. Although a urine pregnancy test was negative, an ultrasound test revealed a 22 cm x 17 cm x 12
cm complex abdominal and pelvic mass. The patient was scheduled for
exploratory laparotomy following a complete workup.
Medical history and examination
The patient was recently diagnosed as having an allergy to intravenous pyelogram dye. She denied the use of any medication. Surgical
history was noncontributory, and family history was unremarkable except for her mother, who had a history of systemic lupus erythematosis.
The patient's gynecologic history involved menarch occurring at age 11
and irregular menstmal periods since then, with menstrual periods lasting anywhere from three to 20 days. The patient's last menstrual period
started on August 3, 1985, and had continued for approximately 30
days.
Upon physical examination the patient complained of lower back
pain, which had been occurring for several months, but denied the presence of urinary symptoms or pedal edema. Examination revealed a
well-nourished and well-developed 14-year-old girl in no apparent distress. Her temperature was 37.3 °C; blood pressure 120/80; pulse 100
beats/min; weight 133.7 kg; and height 70.5 in. Head and neck examination was unremarkable. Thoracic examination revealed the lungs to
be clear. Cardiovascular examination was normal. The patient's abdomen was positive for bowel sounds and was distended with an obvious mass that was tender to palpation. The mass was irregular, higher
on the left than the right side of the abdomen, and measured approximately 36 cm from the top of the superior pubic symphysis. Pelvic examination revealed the cervix to be small and the cul-de-sac apparently
free, but the uterine size could not be assessed because of the abdominal
distention. There was no evidence of any lymphadenopathy, and the extremities were normal.
Hospital course
On admission, laboratory data were as follows: hemoglobin 8.7
g/dL; hematocrit was 26%; mean corpuscular volume was 75.5 U^; and
electrolyte profiles were normal. BUN was 8 g/dL; creatinine was 1.2
mg/dL; glucose 85 mg/dL; and alpha fetoprotein (AFP) was elevated to
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]2,700 mg/dL, with normal being 0 to 20 mg/dL. Intravenous
pyelogram showed arighthydroureter and hydronephrosis. Chest x-ray
and EKG were normal. Barium enema showed an extrinsic compression proximal to and in the midsigmoid area.
On the second day after admission the patient underwent an exploratory laparotomy with a right salpingo-oophorectomy, omentectomy,
appendectomy, and biopsy of the left ovary. Two units of packed RBCs
were given preoperatively and intraoperatively. The tumor was much
larger than described by the ultrasound report. It was mostiy solid with
areas of thin-walled gelatinous cyst on the left superior border. The tu„ior was loosely adherent to the omentum, the small bowel, mesentary,
and sigmoid. Frozen section of the tumor was consistent with endodernial sinus tumor The patient's postoperative hemoglobin stabilized at
9.2 g/dL. She was then seen by the Oncology staff, who recommended
chemotherapy to start two weeks postoperatively. The chemotherapy
recommended was cis-platinum, Velban, and bleomycin. Final pathology was reported as endodermal sinus tumor of the right ovary; all
other biopsied areas were negative for tumor, and cytology of peritoneal
fluid also was negative.
At the time of discharge, our patient's AFP level had decreased to
8100 mg/dL. On October 25, 1985, she was readmitted for the first
course of chemotherapy (Platinol-Velban-bleomycin). AFP was 65
mg/dL. By the second readmission on December 31, 1985, the patient's AFP level had decreased to 3.1 mg/dL. Our patient will continue
on this regimen, and a computed tomography scan will be included in
the follow-up.

Discussion
Endodermal sinus tumor was first classified by Teilum in
1946, who subsequentiy published a series of articles describing
the extraembryonic germ cell origin of the tumor (2-4), thereby
refuting the mesonephric origin proposed by Schiller (5). Since
its classification, endodermal sinus tumor also has been known
as yolk sac tumor, mesoblastoma vetillinum, and Teilum's tumor The association of elevated serum AFP and its immunohistological identification in tumor cell has strengthened evidence that suggests the close relationship of the tumor to the
yolk sac (6,7). The reported age incidence for EST is 16 months
to 46 years, with a peak age incidence of 19 years. Our patient
presented with classic symptoms of EST: abdominal swelling
from rapid tumor growth, abdominal pain secondary to bleeding
into the tumor, anemia, and a palpable abdominal mass.
EST may be pure or mixed. In the mixed variety, other germ
cell tumors such as the teratoma or choriocarcinoma may be encountered. If a choriocarcinoma is present, the patient may present with endocrine disturbances from the elevated HCG. EST
also exhibits a range of histological pattems that differ considerably from each other Two or more patterns may be present
*ithin the same tumor The presence of Schiller Duval bodies
<^an be considered diagnostic for EST. This tumor is not radiosensitive, and radical surgery has not improved the prognosis. The operative procedure can be tailored to the extent of
fte disease and the patient's age. In a young patient with a stage I

disease who has not completed childbearing, a unilateral salpingo-oophorectomy combined with thorough staging biopsies
and cytological washings may provide adequate surgical management (8). The combination chemotherapies most frequentiy
used include 1) actinomycin D , vincristine, and cyclophosphamide; 2) actinomycin D , 5-fluorouracil, and cyclophosphamide; and 3) cis-platinum, bleomycin, and vinblastine
sulfate.
The major unanswered questions conceming this disease include 1) the duration of therapy, 2) the role of second-look
laparotomy, 3) the use of AFP for monitoring, and 4) the effect
of chemotherapy on future ovarian function. The duration of
therapy, which can vary from six to 24 months, will be dictated
by the side-effects of these medications. AFP has been used as
an excellent marker for persistence or recurrence of the disease.
As ESTs recur within one year in 93% of the patients, treatment
should be administered for at least 12 months. Normal menstrual
cycles have occurred following chemotherapy, and normal pregnancies also have been reported. Infertility may occur less frequently following chemotherapy with cis-platinum, bleomycin,
and vincristine than with other therapies that include the alkalating agents (9).
In summary, EST of the ovaries is a highly malignant ovarian
cancer which affects children, adolescents, and young adults.
Because of poor results with radical surgery and improving
prognosis with combination chemotherapy, patients with EST in
the early stages can be offered a more conservative surgical approach. Although the exact answers are not yet available regarding second-look laparotomy, patients who present with initial
elevation of serum AFP should have monthly follow-up of AFP
levels during chemotherapy and after conclusion of such therapy
to mie out possible recurrence of the disease.
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